Investor Presentaiton
Research framework is effective: TYK2 genetics and
SOTYKTU in immunologic diseases
Causal
human biology
Human genetics (P1104A):
implicates TYK2 in multiple
immunologic diseases
Interferon signature
(% reduction)
% pSTAT3+
100
80-
60-
40-
20-
Matching modality
to mechanism
Allosteric inhibitor:
A highly selective
small-molecule drug
~70% TYK2
inhibition I
TYK2
Regulatory
domain
Interferon signature
(% reduction)
Path to clinical
proof-of-concept
Initially psoriasis: now
systemic lupus
erythematosus (SLE)
110
40
20
20
Phenocopies P1104A
homozygous genetic
inhibition
0
-20
-40
-60
-80
BL
4 8 12
20
28 32
44
Week
0 G/G C/G CIC
Active
domain
We now consistently apply this Research framework to all our programs to deliver
transformational medicines with an increased probability of success in development
Ill Bristol Myers Squibb™
Sci Transl Med 2016 Nov; 8(363): 363ra149
PLoS One 2015 April; 10(4): e0122271
Arthritis Rheumatol. 2023 Feb; 75(2): 242-252.
Clin Transl Sci. 2023 Jan; 16(1): 151-164
Not for Product Promotional Use
19View entire presentation